Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21671173 | 0.98 | LMNA (0.52) | LMNASLC1A3SLC1A2SLC1A1PSMB5 | |
| SCHEMBL21671190 | 0.98 | LMNA (0.52) | LMNASLC1A3SLC1A2SLC1A1PSMB5 | |
| SCHEMBL2908890 | 0.98 | LMNA (0.52) | LMNASLC1A3SLC1A2SLC1A1PSMB5 | |
| SCHEMBL8023506 | 0.96 | LMNA (0.44) | LMNASLC1A3SLC1A2SLC1A1PSMB5 | |
| SCHEMBL9967748 | 0.91 | SLC1A3 (0.38) | LMNASLC1A3SLC1A2SLC1A1PSMB5 | |
| SCHEMBL27712709 | 0.87 | LMNA (0.48) | LMNASLC1A3SLC1A2SLC1A1PSMB5 | |
| SCHEMBL3009551 | 0.85 | LMNA (0.47) | LMNASLC1A3SLC1A2SLC1A1PSMB5 | |
| SCHEMBL30458093 | 0.83 | SLC1A3 (0.34) | LMNASLC1A3SLC1A2SLC1A1PSMB5 | |
| SCHEMBL3013492 | 0.83 | LMNA (0.50) | LMNASLC1A3SLC1A2SLC1A1PSMB5 | |
| SCHEMBL8393579 | 0.83 | LMNA (0.46) | LMNASLC1A3SLC1A2SLC1A1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382940-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11046670-B2 | Piperazinyl norbenzomorphan compounds and methods for using the same | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-29 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190077789-A1 | PIPERAZINYL NORBENZOMORPHAN COMPOUNDS AND METHODS FOR USING THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-03-14 | — | — | US | disclosed |
| US-10202378-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20180009805-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| US-9580425-B2 | Pyrido[3,4-b] indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9469641-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150352087-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2015-12-10 | — | — | US | disclosed |
| WO-2009094443-A1 | DIFLUORINATED TRIPEPTIDES AS HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009076166-A2 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076173-A2 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2007146695-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382940-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | EIF2AK2, MAVS, ZC3HAV1 | LMNA 2192/4885SLC1A3 4329/4885SLC1A2 4657/4885 |
| US-20190077789-A1 | PIPERAZINYL NORBENZOMORPHAN COMPOUNDS AND METHODS FOR USING THE SAME | GAP43, NCDN, NLN | LMNA 2290/4885SLC1A3 1973/4885SLC1A2 847/4885 |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | LMNA 2131/4885SLC1A3 3721/4885SLC1A2 4468/4885 |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | LMNA 4458/4885SLC1A3 1879/4885SLC1A2 1252/4885 |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | LMNA 4458/4885SLC1A3 1879/4885SLC1A2 1252/4885 |
| US-11046670-B2 | Piperazinyl norbenzomorphan compounds and methods for using the same | GAP43, NCDN, NLN | LMNA 2290/4885SLC1A3 1973/4885SLC1A2 847/4885 |
| US-10202378-B2 | Therapeutic compounds and uses thereof | TAF1, TAF1L, TAF1B | LMNA 3466/4885SLC1A3 1517/4885SLC1A2 2152/4885 |
| US-20150352087-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | LMNA 4568/4885SLC1A3 198/4885SLC1A2 91/4885 |
| US-20180009805-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | TAF1, TAF1L, TAF1B | LMNA 3466/4885SLC1A3 1517/4885SLC1A2 2152/4885 |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | PRSS1, HPN, SPINT2 | LMNA 3458/4885SLC1A3 3730/4885SLC1A2 4463/4885 |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | LMNA 2131/4885SLC1A3 3721/4885SLC1A2 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.